AgomAb Therapeutics (NASDAQ:AGMB) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of AgomAb Therapeutics (NASDAQ:AGMB) from a hold rating to a sell rating in a research note published on Sunday,Wall Street Zen reports.

A number of other research firms have also recently commented on AGMB. Piper Sandler began coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. B. Riley Financial began coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. HC Wainwright reissued a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, September 16th. Finally, Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating for the company. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, AgomAb Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Price Performance

AGMB stock opened at $10.53 on Friday. AgomAb Therapeutics has a 52-week low of $8.75 and a 52-week high of $17.82. The company’s 50-day simple moving average is $13.15 and its 200-day simple moving average is $12.17.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. On average, sell-side analysts forecast that AgomAb Therapeutics will post -1.76 EPS for the current year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics N.V. (NASDAQ: AGMB) is a clinical-stage biopharmaceutical company developing medicines for diseases involving tissue damage, fibrosis and impaired regeneration. The company’s approach includes modulating biological pathways that influence tissue repair and remodeling, with the goal of addressing conditions with significant unmet medical needs.

AgomAb’s lead clinical program is AGMB-129, an oral, gut-restricted inhibitor of activin receptor-like kinase 5 (ALK5), a receptor involved in transforming growth factor beta signaling.